Skip to main content
. 2022 Nov 23;25(3):656–663. doi: 10.1111/dom.14907

FIGURE 3.

FIGURE 3

Incidence and event rates of hypoglycaemia comparing iGlarLixi with BIAsp‐30 over the 26‐week treatment period (safety population). (A, C) American Diabetes Association (ADA) Level 2 hypoglycaemia (all confirmed <3.0 mmol/L [<54 mg/dL]). (B, D) ADA Level 1 hypoglycaemia (all confirmed <3.9 to ≥3.0 mmol/L [<70 to ≥54 mg/dL]). Top panels: incidence (odds ratio for iGlarLixi versus BIAsp 30); bottom panels: event rates (rate ratio for iGlarLixi versus BIAsp 30). Numerical data are given in Tables S5 and S6. BIAsp, biphasic insulin aspart; BMI, body mass index; CI, confidence interval; eGFR, estimated glomerular filtration rate; FRC, fixed‐ratio combination; iGlarLixi, FRC of insulin glargine 100 U/mL and the glucagon‐like peptide‐1 receptor agonist, lixisenatide; OR, odds ratio; RR, rate ratio